Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

 

• Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate products
  
  
• Cellectis to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential for additional milestones, plus tiered royalties

https://www.globenewswire.com/news-release/2023/11/01/2770788/0/en/Cellectis-Announces-Strategic-Collaboration-and-Investment-Agreements-with-AstraZeneca.html